Today: 11 June 2026
Strategy (MSTR) drops after-hours as bitcoin stays weak and fresh share sales hang over the stock
31 December 2025
2 mins read

Strategy (MSTR) drops after-hours as bitcoin stays weak and fresh share sales hang over the stock

NEW YORK, December 31, 2025, 16:43 ET — After-hours

  • Strategy shares slid 2.3% in after-hours trading, hovering near the day’s lows.
  • A recent SEC filing showed the company sold stock and used the proceeds to buy more bitcoin.
  • Traders are watching bitcoin’s direction into 2026 and whether Strategy keeps tapping its share-sale program.

Strategy Inc shares fell 2.3% to $151.95 in after-hours trade on Wednesday, after swinging between $151.44 and $157.48 earlier in the day. Trading volume topped 15.6 million shares.

The move matters because Strategy has become one of the market’s most visible “bitcoin proxy” stocks — an equity that tends to move with the cryptocurrency — at a time when investors are recalibrating their risk appetite into year-end.

Bitcoin is on track for its first yearly loss since 2022, after struggling to recover from an October peak above $126,000, Reuters reported. “Bitcoin increasingly exhibits the characteristics of a risk asset … with a notable correlation to the U.S. equity market,” Linh Tran, a senior market analyst at XS.com, said in the report. Reuters

In a Dec. 29 filing, Strategy disclosed it sold 663,450 Class A shares for $108.8 million in net proceeds and used the money to buy 1,229 bitcoin at an average price of about $88,568 each. The company said it held 672,497 bitcoin as of Dec. 28, bought for $50.44 billion in total at an average price of $74,997, and had about $11.7 billion still available for issuance under its common-stock sales program.

That sales program is known as an at-the-market offering, or ATM — a mechanism that lets a company sell new shares into the market over time. For existing shareholders, repeated issuance can be dilutive, meaning it spreads ownership across a larger share count.

At bitcoin’s recent levels, Strategy’s disclosed holdings are worth roughly $59 billion, leaving the stock highly sensitive to day-to-day moves in the token as well as shifts in investor tolerance for leverage and dilution.

The feedback loop cuts both ways. When bitcoin rises, Strategy’s ability to raise fresh equity can expand; when the token weakens, the market can push back on additional share sales, tightening the company’s room to maneuver.

Strategy describes itself as a “Bitcoin Treasury Company,” a label for firms that hold bitcoin as a core balance-sheet asset rather than a side investment. Strategy

That positioning has pulled the stock closer to crypto market plumbing than to the software business that originally defined MicroStrategy, the name Strategy used before its rebrand.

Traders also flag round-number levels after Wednesday’s slide. The $150 area is in focus after the stock probed just above it, while the mid-$150s mark the zone the shares struggled to hold into the close.

Next up, investors will watch for the company’s next disclosures around bitcoin purchases and equity issuance, along with any follow-through in the token as markets turn the calendar to 2026.

Strategy is estimated to report earnings on Feb. 4, according to Nasdaq.

For now, the stock’s after-hours drop underscored the same dynamic that has defined recent months: Strategy trades less like a conventional software name and more like a levered bet on bitcoin’s next move.

Stock Market Today

  • Alphabet Stock Slows After Strong Year; Valuation Debates Heat Up
    June 10, 2026, 8:33 PM EDT. Alphabet (GOOGL) shares declined 2.16% over one day and 8.3% over 30 days, cooling off after a robust 101.52% total return over one year. The stock closed at $356.38, trading below the $433 fair value estimated by a popular market narrative that highlights Alphabet's AI advances, cloud profitability, and ad cash flows as growth drivers. However, a more conservative discounted cash flow model values shares at $330.55, suggesting less room for upside. Investors are weighing these conflicting valuations amid potential regulatory risks affecting advertising and emerging competition in AI and cloud sectors. The current market pricing reflects a cautious outlook on Alphabet's future growth prospects despite its long-term strength.

Latest articles

Tech stocks slide after hours, Oracle’s AI spending draws focus

Tech stocks slide after hours, Oracle’s AI spending draws focus

11 June 2026
Semiconductor stocks plunged 3.6%, dragging the S&P 500 technology sector into correction territory—down 11% from its June 2 record—as investors punished AI-linked companies like Oracle and Super Micro Computer for heavy spending and capital raises, signaling a shift in risk appetite amid rising inflation and escalating U.S.-Iran tensions.
Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

11 June 2026
Murphy USA soared 10.04% to $612.16 as investors seized on Casey’s General Stores’ stronger-than-expected fuel margins, spotlighting sector-wide pump profitability; with Murphy’s own first-quarter fuel contribution up 40.6% and margins at 35.0 cents per gallon, the stock’s jump reflects bets that high margins will persist, though volatility in fuel prices remains a key risk.
Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

11 June 2026
Sky Quarry soared 22.44% to $1.91 on record volume, then jumped to $2.38 after hours, as investors bet on a June refinery restart after repairs and a feedstock shortage crushed Q1 revenue to $383; with just $66,828 in cash and “substantial doubt” about its ability to continue, the stock’s fate hinges on hitting its June production target.
Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading
Previous Story

Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop